Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda in recurrent or metastatic HNSCC with PS 2
NCT03813836Phase 2Active, not recruiting
- Sponsor
- University College London
- Start
- Jul 2019
- Primary completion
- Jan 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by University College London. Primary endpoint: Disease Control Rate at 24 weeks. Started Jul 2019; status: active, not recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03813836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03813836.